News
OCGN
0.7743
+0.83%
0.0064
Ocugen, Inc. Reports Favorable Safety and Tolerability Data for OCU410 in Phase 1/2 Clinical Trial for Geographic Atrophy
Barchart · 2d ago
Ocugen’s Phase 1/2 study of OCU410 approved for continuation by DSMB
TipRanks · 2d ago
Ocugen Announced That The Data And Safety Monitoring Board For OCU410 ArMaDa Clinical Trial Recently Convened And Approved The Continuation Of The Second Phase Of The Phase 1/2 Study
Benzinga · 2d ago
OCUGEN INC - NO SERIOUS ADVERSE EVENTS REPORTED FOR OCU410
Reuters · 2d ago
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Barchart · 2d ago
Weekly Report: what happened at OCGN last week (1209-1213)?
Weekly Report · 5d ago
Ocugen's Dr. Shankar Musunuri to Present at Oppenheimer Movers in Rare Disease Summit Discussing Advances in Retinal Disease Therapies
Barchart · 12/11 16:18
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
Barchart · 12/11 06:02
Weekly Report: what happened at OCGN last week (1202-1206)?
Weekly Report · 12/09 10:25
Weekly Report: what happened at OCGN last week (1125-1129)?
Weekly Report · 12/02 10:26
Ocugen, Inc. CEO Dr. Shankar Musunuri to Present at NobleCon20 Emerging Growth Equity Conference
Barchart · 11/27 16:32
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
Barchart · 11/27 06:09
Weekly Report: what happened at OCGN last week (1118-1122)?
Weekly Report · 11/25 10:20
Ocugen, Inc. Receives Orphan Medicinal Product Designation from EMA for OCU410ST in Treating ABCA4-Associated Retinopathies
Barchart · 11/20 16:48
Ocugen announces EMA granted orphan medicinal product designation for OCU410ST
TipRanks · 11/20 12:46
OCUGEN INC - TO PURSUE ACCELERATED MARKETING AUTHORIZATION APPLICATION FOR OCU410ST
Reuters · 11/20 12:30
OCUGEN ANNOUNCES EUROPEAN MEDICINES AGENCY GRANTS ORPHAN MEDICINAL PRODUCT DESIGNATION FOR MODIFIER GENE THERAPY CANDIDATE OCU410ST FOR TREATMENT OF ABCA4-ASSOCIATED RETINOPATHIES INCLUDING STARGARDT DISEASE
Reuters · 11/20 12:30
Ocugen, Inc. Reports Positive Preliminary Data from OCU410 Clinical Trial for Geographic Atrophy in Dry Age-Related Macular Degeneration
Barchart · 11/19 16:16
Ocugen reports positive data for OCU400, OCU410
Seeking Alpha · 11/19 15:10
Ocugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trial
TipRanks · 11/19 12:10
More
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.